Pharmacokinetic Study of Belviq in Adult Korean Volunteers

Phase 1 Completed 25 enrolled IlDong Pharmaceutical Co Ltd

RandomizedSingle-groupDouble-blindTreatment

Summary

A randomized, double-blind, placebo-controlled, single-dose, dose escalation study (Phase I) to evaluate the tolerability and pharmacokinetics of Belviq in adult Korean volunteers.

Timeline

Start: 2013-06
Primary completion: 2013-07
Completion: 2013-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Belviq	Unknown	10 mg	—
Subject	Belviq	Unknown	20 mg	—

Indications

No indication recorded.